![](/images/graphics-bg.png)
Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Joint Authors
Enlund, F.
Holmberg, E.
Andersson, C.
Nyman, J.
Sjögren, H.
Hussein, A.
Hallqvist, A.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-09-17
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background.
The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations.
We wanted to explore the prognostic impact of mutated KRAS in the stage III setting treated with high-dose radiochemotherapy.
Methods.
Samples were obtained from patients participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where patients were treated with induction chemotherapy (carboplatin/paclitaxel) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy (cisplatin/docetaxel) followed by radiotherapy concurrent cetuximab.
The samples were analysed regarding KRAS mutations, EGFR mutations, and EGFR FISH positivity.
Results.
Patients with mutated KRAS had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account.
The prevalence of KRAS mutations, EGFR mutations, and EGFR FISH positivity were 28.8%, 7.5%, and 19.7%, respectively.
Conclusion.
Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy.
The prevalence of KRAS mutations and EGFR mutations are as expected in this Scandinavian population.
American Psychological Association (APA)
Hallqvist, A.& Enlund, F.& Andersson, C.& Sjögren, H.& Hussein, A.& Holmberg, E.…[et al.]. 2012. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-483043
Modern Language Association (MLA)
Hallqvist, A.…[et al.]. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-483043
American Medical Association (AMA)
Hallqvist, A.& Enlund, F.& Andersson, C.& Sjögren, H.& Hussein, A.& Holmberg, E.…[et al.]. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-483043
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-483043